Overview

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanda Pharmaceuticals